We have developed a sensitive HPLC method for measuring methadone in plasma and have used it to establish that there is a linear relationshipbetween plasma concentration and methadone dose over the range of 3-100 mg of methadone per day in a group of 31 addicts. We found a good correlation between dose and plasma concentration (r = 0.89), with the plasma methadone concentration increasing by 0.263 mg/L for every milligram of methadone consumed per kilogram of body weight. Five patients had unexpected high or low concentrations; this finding is discussed.
10-mL polypropylene tubes (LSL Sales Ltd., Rochdale, U.K.) and stored at -20 #{176}C until required for analysis.
Sample treatment. Patients' plasma specimens, quality-control samples (pooled patients' plasma), and plasma methadone standard solution were defrosted and thoroughly mixed (5 s) before centrifugation at room temperature for 2 mm (500 x g). We mixed 2 mL of sample with 0.5 mL of benzhexol (internal standard, 1 mg/L) in aqueous methanol (50/50 by vol) and 0.5 mL of sodium carbonate buffer (1 mol/L, pH 10) in 15-mL acid-washed glass conical tubes with glass stoppers (Orme Scientific, Manchester, U.K.). n-Butyl chloride was used as the solvent extractant in our method (15) . n-Butyl chloride (5 mL) saturated with water was added to the conical tubes and the contents were mechanically mixed for 15 miii, before centrifugation at 4#{176}C for 7 miii (1000 x g). The n-butyl chloride upper layer was aspirated, placed in 5- Methadone was detected by using a silica column and a nonaqueous mobile phase (16). Extracts (20 L) were automatically injected onto the silica column in a mobile phase recycling at 2 mL/min and consisting of methanol/l,2-dichloroethan& isopropanollaqueous (100 gIL) ammonium perchlorate 
Results

Assay Validation
Day-to-day assay reproducibility was assessed by using three different quality-control samples, each made up of pooled patients' plasma. (Insufficient individual patient's plasma was available to make up enough quality-control material to last for the whole study.) The mean ± SD and coefficient of variation (%) for the three samples were as follows: QC-A 0.066 ± 0.005 mg/L (8.2%, n = 8), QC-B 0.069 ± 0.009 mg/L (9.8%, n = 10), and QC-C 0.051 ± 0.005 mg/L (8.1%, n = 14). Withinday assay reproducibility was 3.2% (n = 10).
Accuracy was assessedby measuring methadone in plasma to which this drug had been added over a concentration range of 0.01-0.10 mg/L. The relationship between the quantity of methadone found to that added was linear, with a regression line of y = -0.0004 + 0.925x (r = 0.99, P <0.001). The mean analytical recovery of methadone was 98.4% (SD 5.2%), range 90-110%, and the detection limit of the HPLC assay (signal/noise ratio of 3) was 5 ng.
Several narcotic opioids, their metabolites, and other Previous studies involving fewer patients were conducted at higher dosage concentrations (7) . Figure 4 shows the mean plasma concentrations reported in the literature for different doses of methadone, compared with the more extensive data obtained in our studies. Our data, represented by mean values (calculated from absolute data without the body weight conversion), gave a regression line of y = -0.0385 + 0.0055x (r = 0.92, P <0.001).
DIscussIon
Patients are prescribed methadone on the strength of their opioid dependence.The clinician aims to provide a dose that will protect the addict both from the extremes of a "high" (euphoric feeling sought by heroin misusers) and from the discomfort of withdrawal (17) (14) . * = 1, 80 mg five years (. A = 6,80mg, nine days; 6, 40mg, 11 days (. * = 9,100mg, several months(4).S = 5,100mg, sixweekstoayear(7) on the same fixed doseof methadone was small in most cases,and was partly due to the fact that some patients maintained on a fixed dose of methadone had significantly lower plasma concentrations at the end of the study than at the beginning (19).
The data in the literature are generally in good agreement with ours. Plasma measurements in the literature were collected at the end of a dosing interval (24 h), before a subsequent dose,and after initial dosing. However, the time spent on methadone by these patients before sample collections varied greatly (range, one day to five years). Plasma concentrations that were lower (than in our subjects) for the same methadone dosage were collected from patients who had been receiving methadone for only a short time, and who may not have reached steady-state (Figure 4) .
It is apparent from our results, however, that certain patients had anomalous concentrations of methadone in plasma, either unexpectedly high or low for the given dose. There are no well-established reasons to explain why some patients should have unexpectedly high methadone concentrations in plasma. Supplementation with illicit methadone accounted for the high methadone concentrations in two of the three patients in our study (A and B in Figure 3) ; this was discovered by monitoring compliance in all of our subjects by using a
low-dose phenobarbital marker (20) at concentrations too low to cause enzyme inductions (21).
Chronic liver disease, usually the result of acute viral hepatitis, has been used to explain abnormal methadone kinetics (22), but evidence to support this is conflicting (23, 24) . However, a recent report suggests that liver disease can reduce the clearance of methadone, allowing methadone to reach higher than expected blood concentrations (25) . Increased hematocrit may also change the distribution of methadone within the blood. Because methadone is partially excluded from erythrocytes (26), patients with higher than normal hematocrit might tend to have higher concentrations of free methadone in plasma (27) . High plasma concentrations could also persist if a physiological disturbance caused the release of methadone from its binding sites. The high plasma concentrations in the third patient (C) could not be adequately explained by any of these phenomena.
Many more circumstances have been associated with unexpectedly low plasma methadone concentrations (28) . Early work suggested that patients whose plasma concentrations of drug rapidly decline several hours after a single methadone dose(excessiveclearance) may have low concentrations of methadone at steady-state (29) . Data from plasma concentration vs time were available for one of our patients with low plasma concentrations (E); however, his methadone clearance was 2.87 mL/min per kilogram, similar to the clearance rates reported for other individuals (30) . Many combinations of drugs are prescribed in methadone-treatment programs (34) . For instance, chlorpromazine, amitriptyline, and thioridazine are sometimes used for the relief of anxiety and agitation and to control vomiting, whereas benzodizepines are used to help stabilize sleep patterns and to provide symptomatic relief of anxiety and severe muscle cramps. The benzodiazepines (especially diazepam), which also have known abuse potential (35), are thought to interfere with the normal metabolism of methadone, whereas some are able to modify receptor binding sites (36). Two patients (A and B) who supplemented their methadone dosage misused and had some degree of dependence on benzodiazepines. We do not know if their use of benzodiazepines played any part in their need to supplement their methadone prescription.
Amitriptyline-also prescribed to some of our patients-increases the plasma concentration of alpha1-acid glycoprotein (37) , the main protein binding methadone in blood. Protein binding of methadone may increase under these circumstances and reduce the unbound fraction of the drug in plasma (38) . One of our patients (D) who was prescribed amitriptyline (75 mg/ day) during the study had very low concentrations of methadone in plasma.
The drug interaction of greatest concern in methadone treatment, and the one most difficult to assess, is that between alcohol and methadone. Scientific data indicate that methadone and alcohol appear to enhance the metabolism of one another in a reciprocal fashion (39). Many of the patients in our study consumed alcohol socially (once or twice a week or during the weekend), but this was not possible to quantify. Anecdotally, excessive consumption the previous evening may explain the withdrawal symptom complaints some patients made when they attended the clinic in the morning for their daily dose. Both of the patients with low plasma methadone concentrations (D and E) had histories of alcohol abuse. In one case (E), an attempt to reduce alcohol consumption was made by prescribing disulfiram (Antabuse, 200 mg/day), which is another drug found to cause abnormally low concentrations of methadone in plasma (40).
Possibly, drug interactions such as those we have described contribute to the variation in plasma metha-done concentrations observed between patients on the same fixed dose.
As this study has shown, plasma methadone concentrations obtained at steady-state correlate well with dose per kilogram of body weight, and this relationship can be used to confirm that individuals complaining of withdrawal symptoms do indeed have abnormally low drug concentrations in plasma. Blood sampling would help to detect these individuals and would enable dosages to be amended to suit. The dose of such an individual could be optimized empirically, by blood sampling, and then be fixed once the plasma concentrations fall consistently within the range of values (observed by linear regression) for similar patients. We also recommend that methadone concentrations in plasma should be used to assess patients who are simultaneously taking drugs known to be inducers of microsomal enzymes. These patients form a subgroup that may require higher daily dosesof methadone.
